MX386620B - Composicion de cannabis - Google Patents
Composicion de cannabisInfo
- Publication number
- MX386620B MX386620B MX2019001285A MX2019001285A MX386620B MX 386620 B MX386620 B MX 386620B MX 2019001285 A MX2019001285 A MX 2019001285A MX 2019001285 A MX2019001285 A MX 2019001285A MX 386620 B MX386620 B MX 386620B
- Authority
- MX
- Mexico
- Prior art keywords
- cannabis
- extract
- treating
- relates
- sleep disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370304P | 2016-08-03 | 2016-08-03 | |
| PCT/AU2017/050814 WO2018023163A1 (en) | 2016-08-03 | 2017-08-03 | Cannabis composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019001285A MX2019001285A (es) | 2019-06-13 |
| MX386620B true MX386620B (es) | 2025-03-19 |
Family
ID=61072172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019001285A MX386620B (es) | 2016-08-03 | 2017-08-03 | Composicion de cannabis |
Country Status (15)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102447510B1 (ko) | 2016-08-03 | 2022-09-27 | 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 | 카나비스 조성물 |
| KR20210013645A (ko) | 2016-08-03 | 2021-02-04 | 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 | 카나비스 조성물 |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| WO2018183115A1 (en) * | 2017-03-30 | 2018-10-04 | Ojai Energetics Pbc | Methods and compositions for enhancing health |
| CN110944632A (zh) * | 2017-06-19 | 2020-03-31 | 塞尔达治疗手术有限公司 | 睡眠障碍组合物及其治疗 |
| EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
| WO2019173242A1 (en) * | 2018-03-04 | 2019-09-12 | Cmg Partners, Inc. | Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same |
| US20210251949A1 (en) * | 2018-06-15 | 2021-08-19 | California Cannabinoids | Compositions and Methods for Treatment of Narcolepsy and Related Disorders |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| US20220160648A1 (en) * | 2019-02-13 | 2022-05-26 | Inspired Health Products, LLC | Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof |
| NL2022616B1 (en) | 2019-02-21 | 2020-09-18 | Patrick Alexander Unger | Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia |
| US11554098B2 (en) | 2019-05-03 | 2023-01-17 | HFL Partners, LLC | Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing |
| US12011471B2 (en) * | 2019-12-19 | 2024-06-18 | Atlas365 Incorporated | Extracts enriched with polyphenolic compounds and related methods |
| US11000818B1 (en) * | 2019-12-27 | 2021-05-11 | Cresco Labs Llc | Post processing method for cannabis oil |
| IT202000017137A1 (it) * | 2020-07-15 | 2022-01-15 | Linnea Sa | Estratti di cannabis sativa e loro usi |
| US20230000935A1 (en) * | 2021-07-03 | 2023-01-05 | Joseph Anthony Bidwell | Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2400319B (en) | 2001-05-04 | 2005-06-08 | Gw Pharma Ltd | Cannabinoid-rich extracts |
| JP4411117B2 (ja) * | 2004-03-25 | 2010-02-10 | エスエス製薬株式会社 | 睡眠改善医薬組成物 |
| GB2418612A (en) | 2004-10-01 | 2006-04-05 | Gw Pharma Ltd | Inhibition of tumour cell migration with cannabinoids |
| JP2007246428A (ja) * | 2006-03-15 | 2007-09-27 | Nature Technology Inc | 植物精油成分を有効成分とする経皮吸収型睡眠覚醒用医薬組成物、その組成物を含有する経皮吸収型睡眠覚醒用医薬製剤、及びこれらの製造方法 |
| GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| KR20110120153A (ko) * | 2010-04-28 | 2011-11-03 | 고려대학교 산학협력단 | 리모넨을 함유하는 아데노신 Ａ2ａ 수용체 작용제 |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2496688B (en) | 2011-11-21 | 2016-06-29 | Gw Pharma Ltd | Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases |
| CN104619318A (zh) | 2012-05-03 | 2015-05-13 | 回音制药公司 | 含有δ9-四氢大麻酚的大麻植物分离物及其制备方法 |
| WO2014100231A1 (en) | 2012-12-18 | 2014-06-26 | Kotzker Consulting Llc | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
| US10792318B2 (en) | 2013-03-14 | 2020-10-06 | Sc Laboratories, Inc. | Bioactive concentrates and uses thereof |
| WO2014145490A2 (en) * | 2013-03-15 | 2014-09-18 | Biotech Institute, Llc | Breeding, production, processing and use of specialty cannabis |
| US10265292B2 (en) | 2013-09-18 | 2019-04-23 | The Werc Shop, LLC | Terpene-based compositions, processes methodologies |
| HRP20191097T1 (hr) * | 2013-10-29 | 2019-09-20 | Biotech Institute, Llc | Uzgoj, proizvodnja, obrada i upotreba specijalnog kanabisa |
| RU2016129536A (ru) | 2013-10-31 | 2018-01-31 | Фулл Спектрум Лабораториз, Лтд. | Препараты на основе терпенов и каннабиноидов |
| WO2015200049A1 (en) * | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
| ES2877361T3 (es) | 2014-06-27 | 2021-11-16 | Farm To Farma Inc | Formulaciones de cannabinoides bucales y sublinguales y método para hacer las mismas |
| US11793769B2 (en) * | 2014-08-25 | 2023-10-24 | Jai Shankar Sukul | Device with compositions for delivery to the lungs, the oral mucosa and the brain |
| BR112017008301B1 (pt) * | 2014-10-21 | 2021-12-07 | United Cannabis Corp | Extratos de cannabis e métodos de sua preparação e uso |
| AU2015360349B2 (en) | 2014-12-12 | 2020-10-08 | Ojai Energetics Pbc | Microencapsulated cannabinoid compositions |
| EP3250200A4 (en) | 2015-01-31 | 2018-09-19 | Constance Therapeutics, Inc. | Methods for preparation of cannabis oil extracts and compositions |
| US20160250270A1 (en) | 2015-02-27 | 2016-09-01 | Ebbu, LLC | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| EP3493799A4 (en) | 2016-08-03 | 2020-04-01 | Zelda Therapeutics Operations Pty Ltd | CANNABIS |
| KR20210013645A (ko) | 2016-08-03 | 2021-02-04 | 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 | 카나비스 조성물 |
| KR102447510B1 (ko) | 2016-08-03 | 2022-09-27 | 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 | 카나비스 조성물 |
| CN110944632A (zh) | 2017-06-19 | 2020-03-31 | 塞尔达治疗手术有限公司 | 睡眠障碍组合物及其治疗 |
| US20200276155A1 (en) | 2017-09-15 | 2020-09-03 | Zelda Therapeutics Operations Pty Ltd | Composition and method for treating autism |
| AU2018100924A4 (en) | 2018-07-03 | 2018-08-09 | Zelira Therapeutics Operations Pty Ltd | Composition and method for treating pain |
| MX2022015799A (es) | 2020-06-12 | 2023-04-11 | Zelira Therapeutics Operations Pty Ltd | Composicion y metodo para el tratamiento del dolor cronico. |
| MX2023005339A (es) | 2020-11-06 | 2023-05-22 | Zelira Therapeutics Operations Pty Ltd | Tecnologia de encapsulacion de cannabinoides. |
-
2017
- 2017-08-03 KR KR1020217002290A patent/KR20210013645A/ko not_active Ceased
- 2017-08-03 BR BR112019001852-2A patent/BR112019001852A2/pt not_active Application Discontinuation
- 2017-08-03 AU AU2017307643A patent/AU2017307643B2/en active Active
- 2017-08-03 IL IL296008A patent/IL296008B2/en unknown
- 2017-08-03 PE PE2019000330A patent/PE20200726A1/es unknown
- 2017-08-03 KR KR1020197005589A patent/KR20190035791A/ko not_active Ceased
- 2017-08-03 EP EP17836097.0A patent/EP3493798A4/en active Pending
- 2017-08-03 SG SG11201900665VA patent/SG11201900665VA/en unknown
- 2017-08-03 CN CN201780060688.4A patent/CN109843287A/zh active Pending
- 2017-08-03 MX MX2019001285A patent/MX386620B/es unknown
- 2017-08-03 JP JP2019505171A patent/JP2019523283A/ja active Pending
- 2017-08-03 IL IL264461A patent/IL264461B2/en unknown
- 2017-08-03 WO PCT/AU2017/050814 patent/WO2018023163A1/en not_active Ceased
- 2017-08-03 CA CA3031810A patent/CA3031810A1/en active Pending
-
2018
- 2018-07-03 AU AU2018100923A patent/AU2018100923C4/en not_active Expired
-
2019
- 2019-01-31 CL CL2019000270A patent/CL2019000270A1/es unknown
- 2019-02-01 CO CONC2019/0001044A patent/CO2019001044A2/es unknown
- 2019-10-23 AU AU2019253841A patent/AU2019253841B2/en active Active
-
2021
- 2021-10-01 AU AU2021240297A patent/AU2021240297B2/en active Active
-
2022
- 2022-07-14 US US17/865,024 patent/US11779562B2/en active Active
-
2023
- 2023-09-01 US US18/460,012 patent/US12239628B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX386620B (es) | Composicion de cannabis | |
| MX387442B (es) | Composiciones y tratamientos para el trastorno del sueño | |
| MX386086B (es) | Composicion de cannabis | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| CL2019000268A1 (es) | Composición de cannabis. | |
| FI3883563T3 (fi) | Kannabidiolityyppinen kannabinoidiyhdiste | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX394909B (es) | Uso de la akkermansia pasteurizada para tratar trastornos metabolicos | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| MX391861B (es) | Composiciones de canabinoide y usos | |
| PH12015501354A1 (en) | Antiviral compounds | |
| MX2017007814A (es) | Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| IN2013MU03583A (cg-RX-API-DMAC7.html) | ||
| NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
| IN2013MU01696A (cg-RX-API-DMAC7.html) | ||
| MX392182B (es) | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| IN2013MU00711A (cg-RX-API-DMAC7.html) | ||
| WO2019194773A3 (en) | The combination comprising linagliptin and metformin | |
| NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| EP4461361A3 (en) | Use of vitamin composition in preparing drug for preventing, treating, or delaying alzheimer's disease | |
| MX374938B (es) | Un método para el tratamiento de trastornos del movimiento con befiradol. | |
| MY189372A (en) | Indole derivatives | |
| TR201714882A2 (tr) | Luli̇konazolün topi̇kal farmasöti̇k kompozi̇syonlari | |
| MX2018005345A (es) | Composiciones farmaceuticas de dimetil fumarato. |